Clinical trialNCT00301990UnknownPhase 2Interventional

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

SponsorJonsson Comprehensive Cancer CenterEnrollment65Kidney Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Interleukin-2 may stimulate the white blood cells to kill tumor cells. Giving bevacizumab together with interleukin-2 may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with interleukin-2 works in treating patients with metastatic kidney cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Fairooz F. Kabbinavar, MD
Jonsson Comprehensive Cancer Center
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Jonsson Comprehensive Cancer Center at Ucla
Los Angeles, California, United States
Recruiting
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, United States
Recruiting
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Recruiting
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Recruiting
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Recruiting
Our Lady of Mercy Medical Center Comprehensive Cancer Center
The Bronx, New York, United States
Recruiting
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, United States
Recruiting
Upmc Cancer Centers
Pittsburgh, Pennsylvania, United States
Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Recruiting
University of Virginia Cancer Center
Charlottesville, Virginia, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Aldesleukin →Bevacizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2005
Primary completion: —
Completion: —
Last update posted: 10 Jan 2014
Registered enrollment: 65
Registry id: NCT00301990

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.